EGFR

epidermal growth factor receptor
back to Gene Panel Summary
 
Known Variants (dbSNP)
Harmful Beneficial Normal
- - 123
Novel Variants
Harmful Beneficial Normal
- - 3
Variants by Type Count
Insertions & Deletions 7
Known Variants (dbSNP) 123
With Severity Score 9
Total 126

Known vs. Novel Variants
Known Variants
123
Novel
3

Functional Consequence of Variants
Known Variants
Novel Variants
Known Variants Novel Variants
Harmful, Score > 3
0
0
Beneficial
0
0
Normal, Score 0-2
123
3

Gene Details  

The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene. [provided by RefSeq]

research EGFR on OMIM...
Pharmaceuticals  
FDA approved drugs to treat condition Click on drug names to see more info
Gefitinib

Gefitinib (INN) (pronounced /ɡ??fɪtɨnɪb/) (trade name Iressa) is a drug used in the treatment of certain types of cancer. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor in target cells. It is marketed by AstraZeneca and Teva.

Dasatinib

Dasatinib, previously known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral multi- BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML) after imatinib treatment and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer. The drug is named after one of the inventor chemists, Jagabandhu Das, who was a member of the large discovery and development team at Bristol Myers Squibb.[1]

Eslotionib

Lapatinib

Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours.[1] It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.[2] It is used in combination therapy for HER2-positive breast cancer. It has been approved as front-line therapy in triple positive breast cancer and as an adjuvant therapy when patients have progressed on Herceptin.[3]

Drugs in clinical trials
Many allosteric and covalent inhibitors of EGFr in development

www.ionflux.com